Olivier de Beaumont

Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France.

Pharmaleads SA specializes in the detection, inhibition and modulation of proteases involved in human diseases. It designs and develops analgesic drugs with the aim to revolutionize the treatment of severe pain, with no side effects. The firm's products include high fluorescence substrates for proteases, substrates for BoNT quantification, and EzyBot, a field kit for botulinum toxin detection. The company was founded in 2000 by Bernard Roques and Marie-Claude Fournié-Zaluski and is headquartered in Paris, France.

Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA.

Part of UCB SA, UCB Pharma SA (France) specializes in allergic and respiratory diseases and disorders. The company is based in Nanterre, France.

VAXON Biotech SA develops therapeutic vaccines for the treatment of cancers. It offers treatment for lung, gastric, prostate, breast, renal, liver, and colorectal cancers, using its proprietary technology of optimized cryptic peptides. The firm also provides research and development services. The company was founded by Konstantinos Kosmatopoulos in 2004 and is headquartered in Paris, France.

Convergent Capital SA (CC) is a venture capital investment firm established in 2001 and located west of Paris. CC manages the Convergent Technologies FCPR fund. Their international clientele comprises business angels, entrepreneurs, and institutions including public entities and financial institutions.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

iXBlue SAS manufactures navigation systems using high-spec fiber-optic gyroscopes. The firm offers surface gyrocompasses, photonic components and modules, motion simulators, stabilized platforms, testing and calibration tables, optical fibers and modulators, surface and unmanned underwater vehicle navigators, and space sensors. The company was founded on September 27, 2000 and is headquartered in Saint-Germain-en-Laye, France.

iXCore deals with marine, aeronautics, and fund industries. It offers in maritime, land and space industry, biotechnology, and investment. The company was founded on September 21, 2001 and is headquartered in Marly-le-Roi, IF.

ATANIS Biotech AG is a company based in Oberkirch, Germany that provides a functional allergy diagnostic screening test. The German company's mission is to revolutionize the way allergies are diagnosed and improve treatment success. The company is driven by scientific excellence and provide a proprietary mast cell line that functions as an ex vivo alternative to in vivo testing. Noemi Bachmeier-Zbären, Jean-Pierre Kinet has been the CEOs since 2021. The company was founded in 2021 by Alexander Eggel, Thomas Kaufmann, Noemi Bachmeier-Zbären, Jean-Pierre Kinet.

American Panel Corp. manufactures freezers, warehouses, and refrigeration systems for foodservice and refrigeration industries. The company was by Marvin L. Duncan founded in 1963 and is headquartered in Ocala, FL.

BioWin ASBL operates as non-profit organization, with interest in the health biotechnology sector. With its member, the firm provides support for the funding in the research and development of biomarkers, nano medicine, drug delivery system, novel therapies, medical devices, and information technology applied to human health. The company is headquartered in Gosselies, Belgium.

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Part of CSL Ltd., Sanifit, Inc. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in San Diego, CA.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel.

Cumulus Oncology Ltd. develops oncology drugs. The company was founded by Clare Wareing on November 13, 2017 and is headquartered in Edinburgh, the United Kingdom.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom.

Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France.

Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France.

Qualyst Transporter Solutions LLC provides hepatic drug transporter products and contract research services utilizing the patented B-CLEAR technology. The company was founded by Kenneth R. Brouwer, Gary M. Pollack and Dhiren R. Thakker in 2001 and is headquartered Durham, NC.